Hepatitis B viral X protein (HBx) and the human p53 protein (p53) have been known as a transactivator and as a tumor suppressor, respectively. These two proteins have also been known to interact with each other to neutralize their authentic functions and the p53 represses the HBV enhancer/X promoter activity. Here we report that the promoter activity of the human p53 gene was strongly repressed by the HBx using the chloramphenicol acetyl transferase (CAT) assay. Analyses of serial deletion, site-directed mutagenesis and the heterologous promoter system showed that the site responsible for the repression was the E-box element in the promoter of the p53 gene. In addition, HBx as expected also repressed the activation of the p53 promoter by c-Myc through the E-box element. Northern blot analyses also showed that the expression of the p53 gene in the HepG2-K8 cell line, which expresses HBV genes including HBx, was much more repressed than that of the control cell HepG2. These results with previous data suggest that the shift of the reciprocal inhibitory activities at the levels of proteinprotein interaction and transcription between HBx and p53 may play a decisive role in the HBV-related hepatocarcinogenesis. Oncogene (2000) 19, 468 ± 471.
HBV is a partially double stranded DNA virus that replicates through the reverse transcription of pregenomic RNA (Summers and Mason, 1982) . HBV infects humans and causes a wide range of clinical manifestations, from acute hepatitis to hepatocellular carcinoma (HCC) (Ganem and Varmus, 1987) . HBx has been implicated in HBV-mediated HCC through its ability to induce liver cancer in some transgenic mice (Kim et al., 1991) and to transactivate a variety of viral and cellular promoters (Yen, 1996) . The activity of HBx is also known to be mainly mediated through the binding sites for other transcription factors such as AP-1, NFkB, ATF/CREB and C/EBPa. HBx has been shown to activate AP-1 and NF-kB by means of Ras-mediated signaling pathways (Yen, 1996; Caselmann, 1996; Choi et al., 1997 Choi et al., , 1999 . Activation of Ras by HBx was also shown to increase the cellular level of TBP, which induces RNA polymerase III-dependent transcription (Wang et al., 1997) . Recently, it was reported that activation of Src family kinases by HBx is coupled with the activation of Ras (Klein and Schneider, 1997) .
Wild type p53 is a tumor suppressor protein that induces either apoptosis or cell cycle arrest at the G 1 -S checkpoint in response to DNA damage, thus preventing the transmission of genetic mutations to the daughter cells (Lane, 1992) . The overall function of wild-type p53 therefore appears to be maintenance of the genetic integrity of the cell. Loss of wild-type p53 activity has been identi®ed in over half of the human malignancies examined (Levine, 1993) , consistent with a role for p53 in genome surveillance and the suppression of oncogenic transformation. Hepatocellular carcinoma accounts for over 90% of primary liver cancers and may progress through the inactivation of the p53 gene (Hsu et al., 1991; Aguilar et al., 1994) .
HBx and p53 have been known to directly interact and inhibit their functions (Wang et al., 1994) . In addition, p53 was also known to inhibit the activity of the HBV enhancer/X promoter (Ori et al., 1998) . Here, we investigated if HBx would reciprocally regulate the activity of the p53 promoter and the expression of the p53 in HBV-infected cells.
To study the eect of HBx on the promoter activity of the human p53 gene, a p53 promoter-CAT construct (p53p1CAT) was transfected into HeLa cells with either the HBx expression vector or adenovirus E1A expression vector as a positive control. As shown in Figure 1 , the CAT activity of the p53 promoter was gradually repressed up to fourfold by increasing the HBx expression vector, whereas the activity was increased by adenovirus E1A as previously reported (Furlong et al., 1996) . These results imply that the p53 gene is a target for HBx-mediated repression.
To identify the target sequence of HBx in the upstream region of the p53 gene, deletion mutants of the p53 promoter were prepared and transfected into HeLa cells with the HBx expression vector. HBxspeci®c repression was observed in each construct about 4 ± 6-fold regardless of the promoter strength ( Figure 2a ). These results suggested that the target sequence of HBx-speci®c repression is located in the region of nt 767 to +18, in which there are three transcriptional factor binding sites (CPEp53, NF-kB and E-box element) ( Figure 2b ). As shown in Figure 2a (lanes 1, 3, 5, 7, and 9), deletion of the DNA sequences to 7128 resulted in an increase of CAT activity, which con®rmed a previous report of a negative transcriptional control element upstream of the p53 gene (BienzTadmor et al., 1985) . To determine which site is speci®cally involved in HBx-mediated repression of the p53 promoter activity, we constructed three plasmids bearing mutations on each p53 core promoter element (CPEp53), NF-kB binding site and E-box element ( Figure 2c ). When transfected into the HeLa cells with the HBx expression vector, HBx-speci®c repression was maintained in the p53mCPE and p53mkB mutants, but not in the plasmid p53mEbox (Figure 2c ). These results indicate that the transcriptional repression of the p53 gene by HBx is mediated through the E-box element. The basal promoter activity of p53mCPE was lower than that of the other plasmids ( Figure 2c , lane 3) as previously reported (Sun et al., 1995) .
The eect of HBx was tested on the thymidine kinase (tk) promoter of herpes simplex virus (HSV) with or without the E-box elements. HBx activated the tk promoter about tenfold ( Figure 3a , lanes 1 and 2) as previously reported (Caselmann, 1996) , but the activation by HBx was not shown with pEboxtk, which suggests the repression of HBx through the Ebox element (Figure 3a , lanes 3 and 4). In contrast, HBx activated the pmEboxtk at a level comparable to the pBLCAT2 plasmid ( Figure 3a , lanes 5 and 6). These results showed that the transcriptional repression of the p53 promoter by HBx was mediated through the E-box element.
The bHLH proteins mediate their eects on cellular gene expression through binding to a consensus DNA recognition sequence (5'-CANNTG-3'), called an E-box element, located in the promoter of target genes (Murre et al., 1989) . These proteins have been grouped into three classes based upon the structural characteristic and the pattern of expression, and play an important role in the cell-speci®c expression of many dierent genes and, in some cases, the establishment of dierentiated cell lineages (Weintraub, 1993) . BETA2/ NeuroD, BETA2/E47 and USF bind the E-box sequence of the secretin, insulin, and murine p53 Figure 1 The eect of HBx on the promoter of the human p53 gene. Transcriptional activity of the p53-CAT reporter plasmid (p53p1CAT) was measured in HeLa cells by cotransfection with the HBx expression vector or adenovirus E1A as indicated. Methods: The eukaryotic expression plasmid of HBx was constructed as described previously (Choi et al., 1999) , and the p53p1CAT reporter plasmid was kindly provided by David Reisman (Roy et al., 1994) . All transient transfections and CAT assays were performed as described previously (Choi et al., 1997) . Typically, 2.5 mg of each reporter and 1 mg of each eector plasmid were used. The conversion of chloramphenicol to its acetylated form was quanti®ed by using the BAS radio-analytic imaging system according to the manufacturer's instructions. All experiments were repeated at least three times. A representative autoradiograph is shown, and the relative CAT activities compared with the basal CAT activity in the absence of HBx are the means of three independent results. Standard deviations were 512% in all cases The schematic representation of the transcription factor binding sites and approximate location in the p53 promoter. EBS, ETS-binding site; C/EBP, CCAAT/enhancer binding protein site; CPEp53, p53 core promoter element; arrow, major transcription start site. (c) Transient cotransfection assays were performed using each of the mutant p53 promoter-CAT reporter plasmids and the HBx expression vector as indicated. Methods: Deletion mutants (p53-416, p53-220, p53-128 and p53-67) were prepared by PCR ampli®cation with p53p1CAT as a template and cloned into the pBLCAT2D plasmid. The p53-320 plasmid was constructed by insertion of the HindIII-XbaI fragment of the p53 promoter into the pBLCAT2D plasmid. The numbers in the names of the deletion mutants represent the deletion end points of the 5' region of p53 promoter. The pBLCAT2D plasmid was constructed by deletion of the tk promoter in pBLCAT2. With p53-67 as a template, the p53 promoter fragments for p53mCPE, p53mkB and p53mEbox were prepared by PCR and cloned into the pBLCAT2D plasmid. The p53mCPE, p53mkB and p53mEbox plasmids carry the 85 bp promoter fragment from the p53 gene, with each mutation: the CPEp53 (767 -GCAGGTATTGATGCGCTTAGGGTTTT-736), NF-kB binding site (749 -ATCGTTTTAGG-739) and E-box element (734 -TCTGTG-729). The mutated sequences are underlined genes (Reisman and Rotter, 1993; Naya et al., 1995; Mutoh et al., 1997) . The promoter of the human p53 tumor suppressor gene is also transactivated by the cMyc/Max heterodimer, which binds to the E-box element (Roy et al., 1994) . We therefore investigated whether HBx aects the transactivation of the human p53 gene by c-Myc. The c-Myc expression vector was cotransfected with the plasmid containing the E-box element in the presence or absence of the HBx expression vector. The c-Myc activated the p53 promoter about threefold, presumably through the heterodimerization with endogenous Max protein ( Figure 3b, lane 2) . However, in the presence of HBx, the c-Myc did not activate p53 promoter activity (Figure 3b, lane 3) . Rather it was more repressed in the presence of c-Myc (about 7.5-fold) than in its absence (about ®vefold). The activity of the p53mEbox was neither activated by c-Myc, nor repressed by HBx in the presence of c-Myc (Figure 3b , lanes 4 ± 6). These results suggest that HBx also represses the transcriptional activation of the p53 promoter by the c-Myc, which binds to the E-box element.
To determine whether the endogenous p53 gene is repressed in the HBV-infected cell, the p53 mRNA level was measured by northern blot assay in the human hepatoblastoma cell line HepG2 as a control and in the HepG2-K8 cell which was transfected with HBV and expressing HBx (Kim et al., 1992) . As shown in Figure 4 , the p53 gene was expressed in HepG2, but p53 mRNA was not detectable in HepG2-K8 under the experimental conditions used. In addition, the expression of p53 gene also repressed in a HBx-transfected cell line (data not shown). These results con®rmed that the endogenous p53 gene was also repressed by HBx.
Inactivation of the p53 gene, through mutations, direct interaction and transcriptional repression, is an important event in human cancer, including liver cancer (Levine, 1993) . Several DNA tumor viruses have been shown to interact with the p53 protein, functionally disabling p53 in the infected cells and possibly contributing to virus-dependent transformation. These include SV40 large T Ag, HPV E6, CMV IE2 and adenovirus E1B and E4orf6 (Teodoro and Branton, 1997) . Recent studies also suggest that retroviruses may dier from DNA tumor viruses by in¯uencing the transcription of the p53 gene rather than by directly interacting with p53 protein.
Transactivator protein Tat of the Human immunode®ciency virus, Tax of HTLV type 1 and the core protein of the hepatitis C virus are known to repress the transcription of the p53 gene, suggesting a role in the virus-associated pathology and malignant transformation (Li et al., 1995; Uittenbogaard et al., 1995; Ray et al., 1997) .
Here we demonstrated that HBx repressed the transcription of the human p53 gene through the Ebox element. HBx was also known to interact with the p53 protein, which mutually inhibits their functions (Feitelson et al., 1993; Wang et al., 1994) . In addition, the p53 protein was known to bind and repress the Figure 3 (a) The plasmid pBLCAT2 has a tk promoter (tkp). The plasmid pEboxtk and pmEboxtk have three copies of the Ebox and mutated E-box element, respectively, in front of tkp in the pBLCAT2. The HBx expression vector was transfected with pBLCAT2, pEboxtk or pmEboxtk. (b) The inhibitory eect of HBx on the transcriptional activation of the p53 promoter by cMyc. Each plasmid of p53-67 and p53mEbox was transfected into HeLa cells with c-Myc expression vector in the presence or absence of HBx. Methods: The pEboxtk and pmEboxtk were constructed by inserting trimerized double stranded E-box (5'-GATCCTCCCATGTGCTCAA-3') and mutated E-box (5'-GATCCTCCTCTGTGCTCAA-3') oligonucleotides, respectively, into the BamHI site of pBLCAT2 Figure 4 The endogenous p53 gene is repressed in the HBVinfected cell line. Total RNA was prepared from exponentially growing control cells HepG2 and HepG2-K8 cells infected with HBV. The endogenous p53 mRNA level was analyzed by northern blot assay. The characteristic bands of 18S and 28S ribosomal RNA were observed. Lane 1, HepG2 and lane 2, HepG2-K8. Methods: Total RNA was extracted by the acid guanidinium thiocyanate-phenol-chloroform method and 20 mg of each sample were electrophoresed and stained with ethidium bromide to assess the quality and quantity of the total RNA in the samples (Chomczynski and Sacchi, 1987) . Northern blot assay was performed as described previously (Kim et al., 1992) . The a-32 P-dCTP-labeled human p53 cDNA probe was used HBV enhancer/X promoter (Ori et al., 1998) . Therefore, HBx and p53 can inhibit each other by the protein-protein interaction and the transcriptional repression. The balance of the reciprocal inhibitions between these two proteins may play a decisive role in the development of HBV-related malignancies. Reduced levels of p53 would lead to suppression of cell cycle arrest, leading to rapid progression through the cell cycle without the requisite DNA damage repair prior to genomic replication. This condition may be particularly detrimental to HBV-infected cells, as HBx may disrupt the maintenance of genomic stability by binding damaged DNA and DNA repair proteins such as XAP-1 (Yen, 1996; Caselmann, 1996; Becker et al., 1998) .
